Overview

The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer

Status:
Unknown status

Trial end date:
2018-11-01

Target enrollment:

Participant gender:

Summary

This is a Prospective，Single-center，Single-arm，Open-label exploratory clinical trial evaluating the efficacy and safety of Conversion Surgery for Apatinib plus SOX for patients with unresectable gastric cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Chinese PLA General Hospital

Treatments:

Apatinib
Oxaliplatin